EUVIMEDEUVIMED entdecken
Crossref

Dimethyl fumarate protects from experimental autoimmune encephalomyelitis by modulating colonic immune cells

Amanda Dias Da Rocha Lima iD, Marília G De Oliveira, Breno Ferrari, Roberta C Fonseca, Leah C Beauchamp, Ana Clara Rosa, Fernando Pradella, Toby Black Lanser, Valquíria Aparecida Matheus, Megha Kaul, Maria Yemane iD, Laura Cox und 3 weitere

The Journal of Immunology · 09.02.2026 · 215 (2)

DOI: 10.1093/jimmun/vkaf289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 01.11.2025. Verfasst von Amanda Dias Da Rocha Lima und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Dimethyl Fumarate, Colon, Th17 Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: FAPESP, CAPES-PRINT, Charlotte K. Full Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dimethyl fumarate (DMF) is an oral therapy approved for the treatment of relapsing-remitting multiple sclerosis, and it is known to reduce disease severity in experimental autoimmune encephalomyelitis (EAE). Because self-reactive Th17 lymphocytes are thought to become activated in the gut before migrating to the central nervous system (CNS), we investigated how DMF modulates intestinal immune responses during EAE. Female C57BL/6J mice were immunized with MOG35-55 to induce EAE and treated with DMF (7.5 mg/kg, oral gavage, every 12 h) or vehicle starting at day 3 post-immunization (dpi). At the early chronic phase (d.p.i. 21), continuous DMF treatment reduced disease severity and CNS leukocyte infiltration. Notably, even short-term DMF administration (5 d) attenuated EAE compared to controls. To examine gut-specific effects, we profiled colonic gene expression after 5 d of treatment (dpi 8) using a NanoString autoimmune panel. We found that DMF downregulated genes associated with NF-κB and ERK1/2 signaling, pro-inflammatory cytokine production, and leukocyte migration in intestinal immune (myeloid) and epithelial cells. Flow cytometry analysis further demonstrated reduced interleukin (IL)-23a production by colonic macrophages and dendritic cells, thereby impairing pathogenic Th17 differentiation. Moreover, DMF decreased CXCR3, CCR6, and CXCR6 expression on MOG-reactive (V-β11+) Th17 cells, limiting their migratory potential to the CNS. Together, these findings show that DMF regulates Th17 differentiation and migration within the intestinal compartment, providing a mechanistic link to its protective effects in EAE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalDimethyl FumarateColonTh17 CellsImmunosuppressive AgentsAnimalsMiceFemaleMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinDendritic CellsCell Movement

Stichwörter der Autor:innen

T cell traffickingdimethyl fumarategut mucosamultiple sclerosis

Substanzen

Dimethyl FumarateMyelin-Oligodendrocyte GlycoproteinImmunosuppressive Agents

Autor:innen und Institutionen

  • Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.
  • Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
  • Faculty of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil.
  • Brazilian National Institute of Science and Technology on Neuroimmunomodulation, INCT-CNPq, Brasilia, Brazil.

ORCID-Profile: Amanda Dias Da Rocha Lima, Maria Yemane, Rafael Machado Rezende

Förderung

  • FAPESP
  • CAPES-PRINT
  • Charlotte K. Full Research Fund
  • Water Cove Charitable Foundation
  • Clara E. and John H. Ware Jr. Foundation

Zitieren

APA

Dias Da Rocha Lima, A., De Oliveira, M. G., Ferrari, B., C Fonseca, R., Beauchamp, L. C., Rosa, A. C., Pradella, F., Lanser, T. B., Matheus, V. A., Kaul, M., Yemane, M., Cox, L., Weiner, H., Santos, L., & Rezende, R. M. (2026). Dimethyl fumarate protects from experimental autoimmune encephalomyelitis by modulating colonic immune cells. The Journal of Immunology, 215(2). https://doi.org/10.1093/jimmun/vkaf289

Vancouver

Dias Da Rocha Lima A, De Oliveira MG, Ferrari B, C Fonseca R, Beauchamp LC, Rosa AC, et al. Dimethyl fumarate protects from experimental autoimmune encephalomyelitis by modulating colonic immune cells. The Journal of Immunology. 2026;215(2). doi:10.1093/jimmun/vkaf289

BibTeX
@article{DiasDaRochaLima2026,
  author = {Dias Da Rocha Lima, Amanda and De Oliveira, Marília G and Ferrari, Breno and C Fonseca, Roberta and Beauchamp, Leah C and Rosa, Ana Clara and Pradella, Fernando and Lanser, Toby Black and Matheus, Valquíria Aparecida and Kaul, Megha and Yemane, Maria and Cox, Laura and Weiner, Howard and Santos, Leonilda and Rezende, Rafael Machado},
  title = {Dimethyl fumarate protects from experimental autoimmune encephalomyelitis by modulating colonic immune cells},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {2},
  doi = {10.1093/jimmun/vkaf289}
}
Kostenlos starten →